Allogene Therapeutics, Inc. Fair Value of Long-Term Debt
Allogene Therapeutics, Inc. (ALLO) had Fair Value of Long-Term Debt of $141.40 million as of 2018-12-31, per its 10-K filed 2019-03-08.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2021-02-25
- 2018-12-31: Long-term Debt, Fair Value $141.40M.
- 2018-10-31: Long-term Debt, Fair Value $141.40M.
- 2018-09-30: Long-term Debt, Fair Value $120.20M; Long-term Debt, Fair Value as first filed $139.60K.
- 2018-09-05: Long-term Debt, Fair Value $120.20K.
| Period end | Long-term Debt, Fair Value | Long-term Debt, Fair Value as first filed |
|---|---|---|
| 2018-12-31 | $141.40M 10-K · filed 2019-03-08 | |
| 2018-10-31 | $141.40M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $120.20M 10-K · filed 2021-02-25 | $139.60K 10-Q · filed 2018-11-21 |
| 2018-09-05 | $120.20K 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |